Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05703308
Other study ID # 99008-1023
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 21, 2020
Est. completion date October 22, 2022

Study information

Verified date January 2023
Source Avicenna Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this controlled trial, poor ovarian responder women will be treated with transplantation of autologous menstrual blood stem cells. The investigators will attempt to assess the safety and efficacy of this procedure for the treatment of infertility in POR patients compared to control group.


Description:

With economic development, procreation delays have resulted in more women seeking medical help for infertility treatment. Because the quality and quantity of oocytes are affected by physiological age, despite advances in assisted reproductive technology (ART), managing infertility in women with poor ovarian response (POR) remains a daily challenge for physicians. Adult mesenchymal stromal cell (MSC) therapy has gained particular interest in recent years because it may provide a supportive microenvironment for oocyte development from quiescent primordial follicles. Human MSC transplantation has been shown in preclinical studies to host ovaries and restore their function and structure premature ovarian failure (POF) animal models. Because of their encouraging characteristics such as ease of access, high availability, monthly repeatability of sampling, less ethical considerations, lack of tumor-causing potential, protected property, and significant trans-differentiation capacity, endometrial-derived stromal cells have been considered in a wide range of studies since 2007. Menstrual blood-derived stromal cells (MenSCs), on the other hand, are derived from endometrial tissue and can be collected in a non-invasive manner, making them especially useful in the treatment of reproductive disorders. The investigators attempted to assess the safety and efficacy of intraovarian injection of MenSCs for the treatment of infertility in POR patients based on this evidence. The results of this clinical trial's phases I and II indicated that Men-MSCs could be considered as a potential treatment to restore the fertility capability of POR women. Based on these findings, the investigators have designed a Phase III controlled trial of autologous MenSC therapy for patients with POR.


Recruitment information / eligibility

Status Completed
Enrollment 180
Est. completion date October 22, 2022
Est. primary completion date September 22, 2021
Accepts healthy volunteers No
Gender Female
Age group 25 Years to 45 Years
Eligibility Inclusion Criteria: - Serum AMH < 0.1 ng/ml (at the screening visit and in the absence of OC or sex-steroid intake) - Antral follicular count (AFC) in both ovaries < 4 (at screening visit and in the absence of OC or sex-steroid intake) - Positive history of at least1 standard previous IVF-ET or ICSI-ET - Normal thyroid hormones (TSH and FT4) - Normal level of prolactin, - Normal level of fasting blood sugar - Normal Liver tests (SGOT, SGPT) - Normal level of BUN, creatinine - Negative Infectious tests (HIV, HCV, HBS Ag, VDRL) - Normal coagulation factors (PT, PTT, BT, CT) - Normal serum levels of sodium, potassium, calcium, phosphorus - Negative history of endometrioma or other ovarian cysts - Negative history of previous ovarian surgery - Negative history of cancer - Negative history of a known autoimmune disorder. Exclusion Criteria: - Positive history of hydrosalpinx or anatomical uterine disorders (In vaginal sonography or HSG) - Severe male factors of their husbands (count <15 million/ml)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Autologous Menstrual Blood Stem Cells
The menstrual blood of patients in the MenSCs treatment group was collected in sterile menstrual cups on the second day of menstruation, and directly transferred to a class B clean room for MSC isolation and culture. All cell quality control studies were performed prior to the International Conference of Harmonization Q2 (ICH Q2) guidelines. The density of the final product was 20×106 cells/ml. 150 µl of the prepared suspension was injected intravaginally into each ovary of the patient under general anaesthesia

Locations

Country Name City State
Iran, Islamic Republic of Avicenna Research Institute Tehran

Sponsors (1)

Lead Sponsor Collaborator
Avicenna Research Institute

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Spontaneous pregnancy rate Number of participants that establish a spontaneous clinical pregnancy after stem cell injection 3 months after stem cell injection
Primary Pregnancy rate after ICSI Number of participants that establish a clinical pregnancy after embryo transfer 4 weeks after embryo transfer
Secondary Hormone levels Change from baseline in Anti-Müllerian hormone (AMH), serum follicle stimulating hormone (FSH), and antral follicle count (AFC) 2 and 4 months after stem cell injection
Secondary Number of oocytes Mean number of retrieved COCs per protocol Day 0 after follicle puncture
Secondary Number of MII oocytes Mean number of metaphase II (MII) oocytes per protocol Day 0 after follicle puncture
Secondary Number of embryos Mean number of embryos Day 3-5 after follicle puncture
Secondary Number of high quality embryos number Grade A for cleavage stage embryo, >=3BB for blastocyst Day 3-5 after follicle puncture
Secondary Clinical pregnancy rate The incidence of gestational sac with heartbeat assessed by TVS 4 weeks after embryo transfer
Secondary Biochemical pregnancy rate Incidence of serum beta-hCG test > 25 mIU/ml 12-16 days after oocyte pick-up
Secondary Live birth rate Incidence of the birth of at least one live newborn after 22 weeks of gestation at a follow-up time of 30 days after delivery
Secondary Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Incidence of adverse and serious adverse events with potential relationship to treatment at a follow-up time after 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting NCT05358483 - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Completed NCT03177538 - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders Phase 4
Completed NCT03638856 - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy N/A
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn NCT04753736 - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC N/A
Completed NCT03349905 - Deferred Versus Fresh Embryo Transfers N/A
Completed NCT05076981 - Progesterone Levels During Ovulation and Luteal Phase
Completed NCT04096027 - Cabergoline Before or After Oocyte Collection for Follicular Resolution Phase 4
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Terminated NCT01933633 - Improved Fertility After Exercise in Overweight/Obese Women N/A
Completed NCT01202656 - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization) Phase 1/Phase 2
Terminated NCT01202643 - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF Phase 1/Phase 2
Completed NCT01408615 - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation NCT05698550 - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET Phase 3
Not yet recruiting NCT03910582 - Personalized FET in RIF Patients With Displaced Dating N/A
Completed NCT05440019 - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed NCT05130125 - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer